ORG
CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s
Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden
Glycomine raises $115M to see if it can treat rare glycosylation disorder
Infrequent, GLM101, Glycomine, Congenital disorder of glycosylation type 1A
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird
Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline
Trump pledges his support for a change to the IRA long sought by drugmakers
IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare
Sanofis $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II
Asthma, Amlitelimab, Kymab, sanofi, Immunology
Sanofi tempers its OX40 expectations in asthma after mid-stage miss
Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations
J&J brushes off tariff headwinds with raised forecast, oncology surge
J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions
Sanofi backs $90M financing for I&I biologic developer
sanofi, Series, financing characteristics, II
Illumina and Tempus look beyond cancer in new AI-driven genomics deal
Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market
Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition
Camzyos, Hypertrophic Cardiomyopathy, Myers, Hypertrophic cardiomyopathy without obstruction, Obstructed, Clinical Trials